Monographies on drugs, which are frequently analysed in the course of therapeutic drug monitoring by Rentsch, K et al.








Monographies on drugs, which are frequently analysed in the course of
therapeutic drug monitoring
Rentsch, K; Fathi, M; Grignaschi, N; Magnin, JL; Printzen, G; Thormann, W; Wenk, M; Werner, D
Abstract: In 1995 the working group ”Drug Monitoring” of the Swiss Society of Clinical Chemistry
(SSCC) has already published a printed version of drug monographs, which are now newly compiled and
presented in a standardised manner. The aim of these monographs is to give an overview on the most
important informations that are necessary in order to request a drug analysis or is helpful to interpret
the results. Therefore, the targeted audience are laboratory health professionals or the receivers of
the reports. There is information provided on the indication for therapeutic drug monitoring, protein
binding, metabolic pathways and enzymes involved, elimination half life time and elimination routes as
well as information on therapeutic or toxic concentrations. Because preanalytical considerations are of
particular importance for therapeutic drug monitoring, there is also information given at which time the
determination of the drug concentration is reasonable and when steady-state concentrations are reached
after changing the dose. Furthermore, the stability of the drug and its metabolite(s), respectively, after
blood sampling is described. For readers with a specific interest, references to important publications are
given. The number of the monographs will be continuously enlarged. The updated files are presented on
the homepage of the SSCC (www.sscc.ch). We hope that these monographs are helpful for you handling
therapeutic drug monitoring and look forward to comments of the audience
DOI: https://doi.org/10.1515/jlm.2005.040
Other titles: Monographien über Medikamente, die regelmässig im Rahmen des Therapeutic Drug Mon-
itorings analysiert werden





Rentsch, K; Fathi, M; Grignaschi, N; Magnin, JL; Printzen, G; Thormann, W; Wenk, M; Werner, D
(2005). Monographies on drugs, which are frequently analysed in the course of therapeutic drug moni-
toring. Journal of Laboratory Medicine, 29(4):287-297.
DOI: https://doi.org/10.1515/jlm.2005.040
J Lab Med 2005;29(4):287–297  2005 by Walter de Gruyter • Berlin • New York. DOI 10.1515/JLM.2005.040 2005/33
Article in press - uncorrected proof
Drug Monitoring und Toxikologie Redaktion: V.W. Armstrong
Monographies on drugs, which are frequently analysed in the
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In 1995 the working group ‘‘Drug Monitoring’’ of the
Swiss Society of Clinical Chemistry (SSCC) has already
published a printed version of drug monographs, which
are now newly compiled and presented in a standardised
manner. The aim of these monographs is to give an over-
view on the most important informations that are nec-
essary in order to request a drug analysis or is helpful to
interpret the results. Therefore, the targeted audience are
laboratory health professionals or the receivers of the
reports.
There is information provided on the indication for
therapeutic drug monitoring, protein binding, metabolic
pathways and enzymes involved, elimination half life time
and elimination routes as well as information on thera-
peutic or toxic concentrations.
Because preanalytical considerations are of particular
importance for therapeutic drug monitoring, there is also
information given at which time the determination of the
drug concentration is reasonable and when steady-state
concentrations are reached after changing the dose. Fur-
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fu¨r Klinische Chemie (SGKC)/Working group ‘‘Drug Monitoring’’
of the SSCC.
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thermore, the stability of the drug and its metabolite(s),
respectively, after blood sampling is described.
For readers with a specific interest, references to
important publications are given.
The number of the monographs will be continuously
enlarged. The updated files are presented on the home-
page of the SSCC (www.sscc.ch).
We hope that these monographs are helpful for you
handling therapeutic drug monitoring and look forward to
comments of the audience.
Keywords: acetaminophen; albendazole; amiodarone;
carbamazepin; clozapine; conversion factors; elimination;
flecainide; lidocaine; paracetamol; pre-analytics; protein-
binding; rapamycine; sirolismus; stability; tacrolismus.
Zusammenfassung
Nachdem bereits 1995 eine gedruckte Version von
Arzneimittelmonographien durch die Arbeitsgruppe
Medikamente der Schweizerischen Gesellschaft fu¨r Kli-
nische Chemie (SGKC) erarbeitet worden war, werden
jetzt alle Monographien neu und in einheitlicher Form
erstellt. Ziel dieser Monographien ist es, dem Laborme-
diziner bzw. dem Empfa¨nger der Befunde eine U¨bersicht
u¨ber die wichtigsten Informationen zu geben, die fu¨r die
Veranlassung einer Analyse bzw. fu¨r die Interpretation der
Resultate hilfreich sind.
Es werden klinisch pharmakologische Angaben wie
zum Beispiel Indikation fu¨r das Therapeutic Drug Moni-
toring, Proteinbindungen, Metabolisierungswege und
daran beteiligte Enzyme, Halbwertszeiten und Elimina-
tionswege der Muttersubstanz, sowie Informationen zu
therapeutischen bzw. toxischen Bereichen, zur Verfu¨-
gung gestellt.
Da die Pra¨analytik gerade beim Therapeutic DrugMon-
itoring eine wichtige Rolle spielt, werden auch hier Anga-
ben daru¨ber gemacht, zu welchem Zeitpunkt eine
Bestimmung der Arzneimittelkonzentration sinnvoll ist
und wann nach einer Dosisa¨nderung der steady-state
erreicht ist. Ausserdem werden Angaben u¨ber die Stab-
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Albendazole (data refer to albendazole sulfoxide)
General
• Class of the drug: Anthelmintics
• Synonym(s):
• Common trade name(s) in Germany: Eskazole
• Conversion factors: mg/L=3.77smmol/L
mmol/L=0.265smg/L
Clinical pharmacology
• Indications for TDM: Extrahepatic cholestasis, uncertain response or suspected
toxicity
• Protein binding: Not known
• Elimination half-life: 8.5 h (large interindividual variability)
• Volume of distribution: Not known
• Metabolism:
– Main metabolic pathways: Rapid hepatic transformation of albendazole (achiral) to
albendazole sulfoxide (chiral) and further to albendazole
sulfone (achiral)
– Active metabolite(s)? Albendazole sulfoxide (is determined), albendazole sulfone?
– Inhibitor or inductor of the cytochrome Not known
P450 system?
– Other significant pharmacokinetic interactions: Not known
• Elimination: Via bile, small amount in urine
• Typical therapeutic range: )0.27 mg/L ()1 mmol/L) albendazole sulfoxide for
treatment of echinococcosis
• Potentially toxic concentration: Not known
Pre-analytics
• Time to steady-state since beginning of 2–4 days
treatment or change of posology:
• Time for blood sampling: 4 h after drug administration
• Type(s) of sample: Serum or plasma
• Stability: At 48C many days
References • Marriner SE, Morris DL, Dickson B, Bogan JA.
Pharmacokinetics of albendazole in man. Eur J Clin
Pharmacol 1986;30:705–8
• Cotting J, Zeugin T, Steiger U, Reichen J. Albendazole
kinetics in patients with echinococcosis: delayed
absorption and impaired elimination in cholestasis. Eur J
Clin Pharmacol 1990;38:605–8
• Zeugin T, Zysset T, Cotting J. Therapeutic monitoring
of albendazole: a high-performance liquid chromatography
method for determination of its active metabolite
albendazole sulfoxide. Ther Drug Monit 1990;12:187–90
• Gottstein B. and Reichen J., Echinococcosis/hydatosis.
In G.C. Cook (ed.). Manson’s Tropical Diseases. London:
Saunders 1996:1486–1508
• Bresson-Hadni S, Mignet JP, Vuitton DA. Echinococcosis
of the liver. In: Bircher J, Benhamou JP, McIntyre N,
Rizzetto M, Rode´s J. Oxford Textbook of Clinical
Hepatology. Vol. I (2nd ed.). Oxford: Oxford University Press
1999:1066–76
ilita¨t der Medikamente bzw. ihrer Metaboliten nach der
Blutentnahme gemacht.
Fu¨r die interessierten Leser sind die verwendeten Refe-
renzen aufgefu¨hrt.
Die Zahl der Monographien wird fortlaufend erga¨nzt.
Die aktuellsten Versionen der Monographien sind auf der
Homepage der SGKC abrufbar (www.sscc.ch).
Wir hoffen, dass Ihnen diese Monographien im
Umgang mit dem Therapeutic Drug Monitoring hilfreich
sein werden und freuen uns u¨ber Kommentare und
Bemerkungen.
Schlu¨sselwo¨rter: Albendazol; Amiodaron; Carbamaze-
pin; Clozapin; Elimination; Flecainid; Lidocain; Metabolis-
mus; Paracetamol; Pra¨analytik; Proteinbindung;
Sirolismus; Stabilita¨t; Tacrolismus; Umrechnungs-
faktoren.
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Amiodarone
General
• Class of the drug: Antiarrhythmics
• Synonym(s):
• Common trade name(s) in Germany: Cordarex





• Indications for TDM: Uncertain response or suspected toxicity. Routine
monitoring of amiodarone is questioned.
• Protein binding: 96–98% (a1-acid glycoprotein)
• Elimination half-life: Amiodarone: 55 (21–78) days
DEA: 129 days
• Volume of distribution: 70 L/kg
• Metabolism:
– Main metabolic pathways: Via CYP3A4 to desethyl-amiodarone (DEA) and other
metabolites
– Active metabolite(s)? DEA: 2–3 times more potent than amiodarone
– Inhibitor or inductor of the Inhibitor of CYP2C9, CYP2D6, CYP3A4
cytochrome P450 system?
– Other significant pharmacokinetic interactions: Trimetoprim and ofloxacin decreases renal tubular secretion
• Elimination of parent drug: Hepatic )98%
• Typical therapeutic range: 0.8–2.6 mg/L (1.2–4.0 mmol/L), not defined for DEA
• Potentially toxic concentration: )2.6 mg/L ()4.0 mmol/L) for amiodarone
)2.0 mg/L ()3.2 mmol/L) for DEA (not well defined)
Pre-analytics
• Time to steady-state since beginning Up to six month (!), faster with a loading dose
of treatment or change of posology:
• Time for blood sampling: Before next dose at steady state
• Type(s) of sample: Serum or plasma
• Stability: 2 days at room temperature; decreases up to 23% within a
week (independent of storage temperature); binds to
barrier gels in blood collection tubes!
Remarks During therapy the ratio amiodarone to DEA is )1. May be
used as index for compliance.
References • Natel S, Davies M, Quantz M. The antiarrhythmic efficacy
of amiodarone and desethylamiodarone, alone and in
combination, in dogs with acute myocardial
infarction. Circulation1988;77:200–8
• Somani P. Basic and clinical pharmacology of amiodarone:
relationship of antiarrhythmic effects, dose and drug
concentrations to intracellular inclusion bodies. J Clin
Pharmacol 1998;29:405–12
• Valdes R Jr, Jortani SA, Gheorghiade M. Standards of
laboratory practice: cardiac drug monitoring. National
Academy of Clinical Biochemistry. Clin Chem
1998;44:1096–109
• Campbell TJ, Williams KM. Therapeutic drug
monitoring: antiarrhythmic drugs. Br J Clin Pharmacol
1998;46:307–19
• Ju¨rgens G, Graudal NA, Kampmann JP. Therapeutic drug
monitoring of antiarrhythmic drugs. Clin Pharmacokinet
2003;42:647
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Carbamazepine
General
• Class of the drug: Antiepileptics
• Synonym(s):
• Common trade name(s) in Germany: Fokalepsin, Tegretal, Timonil
• Conversion factors: mg/L=4.23smmol/L
mmol/L=0.236smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, verification of compliance, side
effects, suspicion of toxicity
• Protein binding: 70–80% (mainly to albumin and to a lesser extent to
a1-acid glycoprotein)
• Elimination half-life: – 30 to 45 h during first days of treatment
– 20 h on average when auto-induction of metabolism is
maximal (achieved after around 4 weeks of treatment)
– 10 h on average when given with other inductors
(phenytoin, phenobarbital, ...)
• Volume of distribution: 0.8–1.9 L/kg
• Metabolism:
– Main metabolic pathways: ‘‘10,11-epoxide diol pathway’’ in the liver: oxydation to
carbamazepine 10,11-epoxide mostly by CYP 3A4
followed by almost complete transformation to the transdiol-
10,11 derivative (sdihydroxy-10,11-carbamazepine) and its
glucuronides
– Active metabolite(s)? Carbamazepine 10,11-epoxide
– Inhibitor or inductor of the Inductor of cytochrome CYP 3A4 (auto-induction!)
cytochrome P450 system?
– Other significant pharmacokinetic Numerous interactions, mostly with inductors and inhibitors
interactions: of CYP 3A4
• Elimination of parent drug: Hepatic )98%
Renal -2%
• Typical therapeutic range: 4–10 mg/L (17–42 mmol/L)
• Potentially toxic concentration: )10 mg/L ()42 mmol/L) (variable)
Pre-analytics
• Time to steady-state since beginning 4 weeks (for metabolic induction to be complete)
of treatment or change of posology:
• Time for blood sampling: Before next dose at steady state
• Type(s) of sample: Serum or plasma
• Stability: 48 h at 48C (for longer conservation, freeze at y208C)
Remarks For immunoassays, cross-reaction with the active metabolite
carbamazepine 10,11-epoxide might occur; the extent of this
cross-reaction depends on the method
References • Arzneimittelkompendium Schweiz, Basel: Documed, 2004
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie
und Toxikologie, Grundlagen der Arzneimitteltherapie
(15. Auflage), Basel: Documed, 2001
• Barre et al., in Commission Me´dicaments de la SFBC,
Me´thodes de dosage et suivi the´rapeutique: aminosides,
antie´pileptiques, he´te´rosides cardiotoniques, isoniazide,
the´ophylline., Expansion Scientifique Francaise, 1989, 26–48¸
• MacKichan and Kutt. In: Taylor WJ, Finn AL. Individualizing
Drug Therapy – Practical Applications of Drug
Monitoring, Vol. 2, New York: Gross, Townsend, Frank,
Inc 1981, 1–25
• Regenthal R, Krueger M, Koeppel C, Preiss R. Drug levels:
therapeutic and toxic serum/plasma concentrations of
common drugs. J Clin Monit Comput 1999;15:529–44
• Warner A, Privitera M, Bates D. Standards of laboratory
practice: antiepileptic drug monitoring. National Academy
of Clinical Biochemistry Clin Chem 1998;44:1085–95
• Yukawa E. Optimisation of antiepileptic drug therapy. The
importance of serum drug concentration monitoring. Clin
Pharmacokinet 1996;31:120–30
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Clozapine
General
• Class of the drug: Antipsychotics
• Synonym(s):
• Common trade name(s) in Germany: Leponex, Elcrit





• Indications for TDM: Individual dose adaptation, verification of compliance, side
effects, suspicion of toxicity
• Protein binding: 95% (a1-acid glycoprotein)
• Elimination half-life: 6–26 h
• Volume of distribution: 1.6 L/kg
– Metabolism:
– Main metabolic pathways: CYP1A2 (Norclozapine), CYP3A4
(Clozapine-N-oxide), CYP2D6
– Active metabolite(s)? Norclozapine (partial activity) (is determined)
– Inhibitor or inductor of the Not yet found
cytochrome P450 system?
– Other significant pharmacokinetic interactions: Cigarette smoking decreases clozapine serum levels
– Elimination of parent drug: Hepatic )30%
Renal )50%
– Indicative therapeutic range: 350–810 mg/L (1.07–2.48 mmol/L) (Clozapine)
– Indicative toxic concentration: )1000 mg/L (3.1 mmol/L) (Clozapine)
Pre-analytics
– Time to steady-state since beginning 3–5 days
of treatment or change of posology:
– Time for blood sampling: Before next dose at steady state
– Type(s) of sample: Serum or plasma
– Stability: At 48C several days in serum
Remarks Plasma levels are 10% higher (clozapine) and 16% higher
(norclozapine) than serum levels.
References • Arzneimittelkompendium Schweiz, Basel: Documed 2004
• Baselt RC. Disposition of Toxic Drugs and Chemicals in
Man, 6th edition, Foster City, (USA): Biomedical
Publikations 2002
• Kaladjian A, Bery B, Deturmeny E, Bruguerolle B.
Clozapine monitoring: plasma or serum levels? Therap
Drug Monit 1999;21:327–9
• Mitchell P. Therapeutic drug monitoring of psychotropic
medications. Br J Clin Pharmacol 2001;52:45S
• Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner
I, Gerlach M, et al. The AGNP-TDM expert group
consensus guidelines: therapeutic drug monitoring in
psychiatry. Pharmacopsychiatry 2004;37:243–65
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Flecainide
General
• Class of the drug: Antiarrhythmics
• Synonym(s):
• Common trade name(s) in Germany: Tambocor
• Conversion factors: mg/L=2.41smmol/L
mmol/L=0.414smg/L
Clinical pharmacology
• Indications for TDM: Dose adaptation during reduced liver and/or kidney function.
Avoidance of toxic levels in CYP2D6 poor metabolizers
• Protein binding: 40% (a1-acid glycoprotein)
• Elimination half-life: 12–20 h
• Volume of distribution: 8.5 L/kg
• Metabolism:
– Main metabolic pathways: Via CYP2D6 (stereoselective) and conjugated metabolites
– Active metabolite(s)? Meta-o-dealkyl-flecainide (activity approx. 20%, clinically
not relevant)
– Inhibitor or inductor of the Inhibitor of CYP2D6
cytochrome P450 system?
– Other significant pharmacokinetic Inhibitors of CYP2D6 (e.g., amiodarone, cimetidine)
interactions: increase flecainide serum levels
• Elimination of parent drug: Hepatic )70%
Renal -30%
• Typical therapeutic range: 0.2–0.8 mg/L (0.5–1.9 mmol/L)
• Potentially toxic concentration: )1 mg/L ()2.4 mmol/L)
Pre-analytics
• Time to steady-state since beginning 3–5 days
of treatment or change of posology:
• Time for blood sampling: Before next dose at steady state
• Type(s) of sample: Serum or plasma
• Stability: Several days at 48C
Remarks Heart, kidney, and liver failure reduce flecainide clearance
References • Valdes R Jr, Jortani SA, Gheorghiade M. Standards of
laboratory practice: cardiac drug monitoring. National
Academy of Clinical Biochemistry. Clin Chem 1998;44:
1096–109
• Campbell TJ, Williams KM. Therapeutic drug
monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 1998;
46:307–19
• Ju¨rgens G, Graudal NA, Kampmann JP. Therapeutic
drug monitoring of antiarrhythmic drugs.
Clin Pharmacokinet 2003;42:647–63
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Lidocaine
General
• Class of the drug: Antiarrhythmic drugs, local anesthetics
• Synonym(s): Lignocaine
• Common trade name(s) in Germany Xylocain
• Conversion factors: mg/L=4.27smmol/L
mmol/L=0.234smg/L
Clinical pharmacology
• Indications for TDM: To control lidocaine levels after heart failure, shock, hepatic
disease or suspected toxicity. Drug monitoring is not
routinely performed
• Protein binding: 60–70% (a1-acid glycoprotein)
• Elimination half-life: 1–2 h
• Volume of distribution: 1.1 L/kg
• Metabolism:
– Main metabolic pathways: Via CYP1A2 and CYP3A4 to monoethylglycinexylide
(MEGX) and glycinexilide (GX)
– Active metabolite(s)? MEGX and GX
– Inhibitor or inductor of the Not known
cytochrome P450 system?
– Other significant pharmacokinetic Inducers or inhibitors of CYP1A2 or CYP3A4 can
interactions: influence lidocaine levels
• Elimination of parent drug: )97% hepatic
-3% renal
• Typical therapeutic range: 2–5 mg/L (8.5–21 mmol/L)
• Potentially toxic concentration: )6 mg/L ()26 mmol/L)
Pre-analytics
• Time to steady-state since beginning 30–90 min after a loading dose; 5–10 h without an initial
of treatment or change of posology: loading dose
• Time for blood sampling: 2 h after loading dose or 5–10 h after beginning of the
infusion (without an initial loading dose)
• Type(s) of sample: Serum or plasma
• Stability: 6 h at 48C; 8 weeks at y258C.
Binds to barrier gels in blood collection tubes!
Remarks Determination of MEGX can be used as liver function test
(e.g., after liver transplantation)
References • Valdes R Jr, Jortani SA, Gheorghiade M. Standards of
laboratory practice: cardiac drug monitoring. National
Academy of Clinical Biochemistry. Clin Chem 1998;
44:1096–109
• Campbell TJ, Williams KM. Therapeutic drug
monitoring: antiarrhythmic drugs. Br J Clin Pharmacol
1998;46:307–19
• Ju¨rgens G, Graudal NA, Kampmann JP. Therapeutic drug
monitoring of antiarrhythmic drugs. Clin Pharmacokinet
2003;42:647–63
• Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M,
Palatini P. Cytochrome P450 1A2 is a major determinant
of lidocaine metabolism in vivo: effects of liver function.
Clin Pharmacol Ther 2004;75:80–8
• Tanaka E, Inomata S, Yasuhara H. The clinical importance
of conventional and quantitative liver function tests in liver
transplantation. J Clin Pharm Therap 2000;25:411–9
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Paracetamol (DCI)
General
• Class of the drug: Analgesics
• Synonym(s): Acetaminophen, N-acetyl-p-aminophenol
• Common trade name(s) in Germany: numerous
• Conversion factors: mg/L=6.62smmol/L
mmol/L=0.151smg/L
Clinical pharmacology
• Indications for TDM: Suspicion of toxicity
• Protein binding: 5–15% at therapeutic concentration
until 50% in overdose
• Elimination half-life: 1–4 h (may be higher in case of intoxicationstoxicity
indication)
• Volume of distribution: 0,75–1 L/kg
• Metabolism:
– Main metabolic pathways: Extensive by hepatic route; forms inactive sulfates (main
children pathway) and glucuronides (main adult pathway)
– Active metabolite(s)? Toxic metabolite in case of intoxication (oxydase pathway,
essentially CYP2E1): N-acetyl-p-benzoquinonimine,
normally rapidly detoxified by glutathione in the liver. In
overdose, production of the toxic metabolite exceeds
glutathione capacity and the metabolite reacts directly with
hepatic macromolecules, causing liver injury.
– Inhibitor or inductor of the No
cytochrome P450 system?
– Other significant pharmacokinetic Enzymatic inductors may promote oxidative pathway
interactions: (CYP2E1) to toxic metabolite.
Chronic alcoholism: enzymatic induction, lowered
glutathione capacity, higher risk of liver injury
• Elimination of parent drug: Hepatic )90%
Renal -5%
• Typical therapeutic range: 5–20 mg/L
• Potentially toxic concentration: Nomogram for prediction of acetaminophen hepatotoxicity
(Figure 1):
– )150–200 mg/L 4 h after ingestion
(Alcoholic, cirrhotic, associated
hepatotoxic substances: )100 mg/L at 4 h)
– )100 mg/L at 8 h
– )50 mg/L at 12 h
– )30 mg/L at 15 h
Figure 1 The Rumack-Matthew nomogram relating expected
severity of liver toxicity to serum paracetamol concentrations.
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Pre-analytics
• Time to steady-state since Acute intoxication: modified kinetic if massive ingestion
beginning of treatment or change of Therapeutic dosage: time to steady state 5–20 h (orally,
posology: continuous treatment)
• Time for blood sampling: Acute intoxication: min. 4 h after ingestion, max. 24 h.
Therapeutic: 1 h after ingestion (Cmax)
• Type(s) of sample: Serum or plasma
• Stability: 8 h at room temperature, 48 h at 4–88C, for longer
conservation freeze at y208C
Remarks Variable, method related, cross-reactivity with toxic metabolite
Possible interference (false positive) of hyperbilirubinemic
samples (Clin Chem 49 (2003) 695)
Antidotes: N-acetylcysteine
References • Fenton J. The laboratory and the poisoned patient,
Washington: AACC Press 1998, 31–36
• Olson K. Poisoning and drug overdose, Stanford (USA):
Appleton&Lange 1990:57–58
• Tietz NW. Clinical guide to laboratory tests, 3rd ed.,
Philadelphia: Saunders 1995:788–9
• Arzneimittelkompendium Schweiz, Basel:
Documed 2004
• White S, Wong SHY. Standards of laboratory practice:
analgesic drug monitoring. National Academy of Clinical
Biochemistry. Clin Chem 1998;44:1110–23
• Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT.
Contribution of CYP2E1 and CYP3A to acetaminophen
reactive metabolite formation. Clin Pharmacol Ther
2000;67:275–82
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Sirolimus
General
• Class of the drug: Immunosuppressants
• Synonym(s): Rapamycine
• Common trade name(s) in Germany: Rapamune
• Conversion factors: mg/L=1.09snmol/L
nmol/L=0.91smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, symptoms of
rejection or toxicity
• Protein binding: 95–97% localized in erythrocytes; in plasma
92% bound to albumin
• Elimination half-life: 46–78 h
• Volume of distribution: 5–19 L/kg
• Metabolism:
– Main metabolic pathways: Liver, mainly through CYP3A4
– Active metabolite(s)? Desmethylmetabolites and hydroxymetabolites
represent a maximum of 30% of sirolimus activity
– Inhibitor or inductor of the Inductor of CYP3A4
cytochrome P450 system?
– Other significant pharmacokinetic PGP substrate and inhibitor
interactions:
• Elimination of parent drug: Hepatic )90%
Renal -3%
• Typical therapeutic range: Dependent on combination therapy and indication
• Potentially toxic concentration: )30 mg/L
Pre-analytics
• Time to steady-state since ;4 days
beginning of treatment or change
of posology:
• Time for blood sampling: Before next dose at steady state
• Type(s) of sample: Whole blood on EDTA
• Stability: 1 day at 258C, 2–3 days at 48C, for longer
conservation freeze at y208C
Remarks Samples should be shipped frozen
References • Arzneimittelkompendium Schweiz, Basel:
Documed 2004
• Napoli KL, Taylor PJ. From beach to bedside:
history of the development of sirolimus. Ther
Drug Monit 2001;23:559–86
• Macphee IA, Fredericks S, Tai T, Syrris P,
Carter ND, Johnston A. Tacrolimus
pharmacogenetics: polymorphisms associated
with expression of cytochrome p4503A5 and
P-glycoprotein correlate with dose requirement.
Transplantation 2002;74:1486–9
• Ingle GR, Sievers TM, Holt CD. Sirolimus:
continuing the evolution of transplant
immunosuppression. Ann Pharmacother
2000;34:1044–55
• Marzolini C, Paus E, Buclin T, Kim RB.
Polymorphisms in human MDR1 (P-
glycoprotein): recent advances and clinical
relevance. Clin Pharmacol Ther 2004;75:13–33
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Tacrolimus
General
• Class of the drug: Immunosuppressants
• Synonym(s): FK506
• Common trade name(s) in Germany: Prograf
• Conversion factors: mg/L=1.24snmol/L
nmol/L=0.80smg/L
Clinical pharmacology
• Indications for TDM: Individual dose adaptation, symptoms of rejection or toxicity
• Protein binding: 92–98% localized in erythrocytes; in plasma 98.8% bound to
albumin
• Elimination half-life: 12–15 h
• Volume of distribution: 2.5 L/kg
• Metabolism:
– Main metabolic pathways: Liver, high affinity for CYP3A4
– Active metabolite(s)? 31-O-desmethyltacrolimus, has a similar activity to tacrolimus
– Inhibitor or inductor of the Strongly inhibitor for CYP1A2 and 3A4
cytochrome P450 system?
– Other significant pharmacokinetic PGP substrate and inhibitor
interactions:
• Elimination of parent drug: Hepatic )99%
Renal -1%
• Typical therapeutic range: Dependent on combination therapy and indication
• Potentially toxic concentration: )30 mg/L
Pre-analytics
• Time to steady-state since ;3 days
beginning of treatment or change of posology:
• Time for blood sampling: Before next dose at steady state
• Type(s) of sample: Whole blood on EDTA
• Stability: 5 days at 258C
References • Arzneimittelkompendium Schweiz, Basel: Documed
2004
• Holt DW, Armstrong VW, Griesmacher A, Morris RG,
Napoli KL, Shaw LM, et al. International Federation
of Clinical Chemistry/International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
working group on immunosuppressive drug monitoring.
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